On October 15, 2026, a European Medicines Agency committee recommended approving Revolution Medicines' pancreatic cancer drug Rasonque for adults whose disease worsened after prior treatment. The recommendation brings the RAS-protein inhibitor closer to availability across the 27-nation European Union. Rasonque was previously approved in the U.S. in August 2026 under expedited review. In a 500-patient late-stage study, Rasonque nearly doubled median survival to 12.4 months from 6.7 months with chemotherapy.
EMA approval recommendation for Rasonque
- ▪On October 15, 2026, a European Medicines Agency committee recommended approving Revolution Medicines' pancreatic cancer drug Rasonque in the European Union
- ▪The European Medicines Agency panel's October 15, 2026 recommendation moves Revolution Medicines' pancreatic cancer treatment Rasonque closer to market authorization across the 27-nation European Union
RAS protein blocking mechanism
- ▪Revolution Medicines tested its drug Rasonque in a late-stage clinical trial targeting patients with an aggressive form of pancreatic cancer driven by a RAS G12 mutation
- ▪Revolution Medicines' pancreatic cancer drug Rasonque works by blocking RAS proteins, which drive cancer-cell growth
Late-stage trial survival outcomes
- ▪In a late-stage clinical trial of 500 patients, Revolution Medicines' drug Rasonque extended median survival to 12.4 months compared to 6.7 months for patients receiving chemotherapy
- ▪Revolution Medicines' final-stage trial showed Rasonque nearly doubled the standard survival time for patients with aggressive pancreatic cancer
US regulatory approval timeline
- ▪Revolution Medicines' pancreatic cancer drug Rasonque received U.S. approval in August 2026 through an expedited review process
- ▪United States regulators approved Revolution Medicines' pancreatic cancer drug Rasonque in August 2026
Pancreatic cancer treatment indication
- ▪The European Medicines Agency recommended Rasonque specifically for adult patients with pancreatic cancer that has spread and worsened after at least one prior treatment
- ▪Revolution Medicines' drug Rasonque is indicated for adults whose pancreatic cancer has progressed after earlier medical therapy
Story comments
Loading comments…